The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the regulatory shift toward less harmful tobacco alternatives, the US FDA issued modified risk tobacco product (MRTP) orders for 20 variants of Philip Morris International’s ZYN nicotine pouches. These orders allow the company to market these products with explicit claims of reduced health risks compared to traditional cigarettes. The decision followed a rigorous scientific review confirming that marketing ZYN with reduced-risk status is appropriate for the protection of public health, making it the first nicotine pouch to receive such authorization.
This approval comes amid intensifying competition in the alternative nicotine market, as rivals like Altria (MO) push their 'On!' product line. Per market data, Philip Morris (PM) shares closed at $182.27 on July 2, 2026, maintaining stability despite broader sector pressures. ZYN has become a primary growth engine for the company in the US, with nicotine pouch shipments surging by over 80% in the first quarter of 2024 according to previous earnings reports (external search).
Investors should watch support levels for PM near $179.52, the low reached during the July 2, 2026 session, while $183.83 serves as immediate resistance. Looking ahead at the economic calendar, market sentiment may be influenced by the Chinese Manufacturing PMI data on June 30, which impacts global demand outlooks. Traders are also monitoring upcoming Fed speeches for insights into consumer spending trends that could affect the broader consumer staples sector.